Oragenics is a biopharmaceutical company developing medical treatments for neurological diseases, with its principal focus on ONP-002 for mild traumatic brain injury. The company conducts research, development, and regulatory work toward clinical advancement of its lead neurology asset, outsourcing drug manufacturing to a single partner while funding operations through equity and debt financing. As an early-stage development company, Oragenics incurs substantial expenses on preclinical studies, clinical trials, regulatory approvals, and personnel costs, with revenues dependent on eventual commercialization success following lengthy development timelines and regulatory approval processes.